-
1
المؤلفون: Perez-Gracia, Jose Luis, Sanmamed, Miguel F., Bosch Campos, Ana, Patiño-Garcia, Ana, Schalper, Kurt A., Segura, Victor, Bellmunt, Joaquim, Tabernero, Josep, Sweeney, Christopher J., Choueiri, Toni K., Martín, Miguel, Fusco, Juan Pablo, Rodriguez-Ruiz, Maria Esperanza, Calvo, Alfonso, Prior, Celia, Paz-Ares, Luis, Pio, Ruben, Gonzalez-Billalabeitia, Enrique, Gonzalez Hernandez, Alvaro, Páez, David, Piulats, Jose María, Gurpide, Alfonso, Andueza, Mapi, Velasco, Guillermo, Pazo, Roberto, Grande, Enrique, Nicolas, Pilar, Abad-Santos, Francisco, Garcia-Donas, Jesus, Castellano, Daniel, Pajares, María J., Suarez, Cristina, Colomer, Ramon, Montuenga, Luis M., Melero, Ignacio
المصدر: Cancer Treatment Reviews. 53:79-97
مصطلحات موضوعية: Biomarkers, Clinical trial design, Extreme phenotypes, Mutation, Rearrangement, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology
الوصف: The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework—the DESIGN guidelines—to standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field.
الوصول الحر: https://lup.lub.lu.se/record/d6c3669d-f7c3-4e6e-bceb-ef0be5a05b8bTest
http://dx.doi.org/10.1016/j.ctrv.2016.12.005Test -
2
المؤلفون: Castellano, Daniel, Sepulveda, Juan Manuel, García-Escobar, Ignacio, Rodriguez-Antolín, Alfredo, Sundlöv, Anna, Cortes-Funes, Hernán
المصدر: The Oncologist. 16(2):45-136
مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bone Neoplasms, Bone Remodeling, Breast Neoplasms, Clinical Trials as Topic, Denosumab, Humans, Male, Multiple Myeloma, Osteoclasts, Prostatic Neoplasms, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't, Review, Medicin och hälsovetenskap, Klinisk medicin, Cancer och onkologi, Medical and Health Sciences, Clinical Medicine, Cancer and Oncology
الوصف: The diagnosis of bone metastases is an event with certain consequences for the patient. They often mean pain and can also mean pathological fractures, hypercalcemia, and spinal cord compression, all synonymous with a diminished quality of life and often also hospitalization. Since the advent of the intravenous bisphosphonates, things began to look a bit brighter for patients with bone metastases-bone destruction was kept at bay a little longer. The next generation of bone metastasis treatments is well on its way in clinical development, and among them, the most advanced drug is denosumab. Denosumab is a fully human monoclonal antibody that inhibits osteoclast maturation, activation, and function by binding to receptor activator of nuclear factor kappa B ligand, with the final result being a reduced rate of bone resorption. In this review, we give an overview of relevant preclinical and clinical data regarding the use of denosumab in patients with solid tumors in general and prostate cancer in particular.
الوصول الحر: https://lup.lub.lu.se/record/5f83e8c2-14ad-4ae2-a57f-259c371876b2Test
http://dx.doi.org/10.1634/theoncologist.2010-0154Test -
3
المؤلفون: Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Van Der Kwast, Theo, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, De Visschere, Pieter J. L ., Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L, Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, Oyen, Wim J.G., Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Vahr Lauridsen, Susanne, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Vives Rivera, Franklin A., Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, Horwich, Alan
المصدر: European Urology. 77(2):223-250
الوصف: BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference.SETTING: Online Delphi survey and consensus conference.PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), and 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease, and the evolving role of checkpoint inhibitor therapy in metastatic disease.CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.PATIENT SUMMARY: This report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of bladder cancer. It is anticipated that these statements will provide further guidance to health care professionals and could help improve patient outcomes until a time when good-quality evidence is available.
وصف الملف: print
-
4
المؤلفون: Fizazi, Karim, Abrahamsson, Per-Anders, Ahlgren, Göran, Bellmunt, Joaquim, Castellano, Daniel, Culine, Stephane, de Wit, Ronald, Gillessen, Silke, Gschwend, Juergen E, Hamdy, Freddie, James, Nicholas, McDermott, Raymond, Miller, Kurt, Wiegel, Thomas, Wirth, Manfred, Tombal, Bertrand
المصدر: European Urology. 67(5):904-912
مصطلحات موضوعية: Medicin och hälsovetenskap, Klinisk medicin, Urologi och njurmedicin, Medical and Health Sciences, Clinical Medicine, Urology and Nephrology
الوصف: Phase 3 trials have made major contributions to advances in prostate cancer (PCa). However, funding limitations and excess bureaucracy are now making it difficult to conduct trials.
الوصول الحر: https://lup.lub.lu.se/record/4691595Test
http://www.ncbi.nlm.nih.gov/pubmed/25218582?dopt=AbstractTest
http://dx.doi.org/10.1016/j.eururo.2014.08.076Test -
5
المؤلفون: Öberg, Kjell, Castellano, Daniel
المصدر: Cancer Metastasis Review. 30(1):3-7
مصطلحات موضوعية: Biomarkers, GEP-NETs, Molecular imaging, Neuroendocrine tumor, TNM staging, WHO classification, MEDICINE, MEDICIN
الوصف: Neuroendocrine tumors (NETs) consist of a heterogeneous group of malignancies with various clinical presentations and growth rates. The incidence has been estimated to 2.5-5 per 100,000 people per year and prevalence of 35 per 100,000. The largest group is the gastroenteropancreatic NETs. Small intestinal NETs are the most common followed by pancreatic NETs in the gastrointestinal tract. A classification system (World Health Organization) was established in year 2000 and recently updated in 2010, taking into consideration the histopathology and tumor biology of the tumors. To further refine the classification a "tumor node metastasis" staging has been suggested by the European Neuroendocrine Tumor Society. The same organization has also proposed a grading system (G1, G2, and G3). The diagnosis of a NET is based on histopathology on tumor specimens, circulating biomarkers as well as imaging. Traditional radiology, such as computerized tomography and magnetic resonance imaging, is still the basis but is complemented with somatostatin receptor scintigraphy and positron emission tomography with specific isotopes such (68)Ga-DOTA-octreotate, F18-dopamine, or C11-5 hydroxytryptamine. Molecular imaging will increase in importance in the near future. There is still an unmet need for more sensitive biomarkers for diagnosis and follow-up.
وصف الملف: print
